Current Edition


Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Dive Brief: Shares in Nektar Therapeutics fell by more than half Monday morning after the San Francisco biotech company and partner Bristol Myers Squibb disclosed …

Continue Reading →

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers’ acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol …

Continue Reading →
anti-inflammatory medicine

Bristol Myers’ top autoimmune drug prospect takes a hit in mid-stage trial

Deucravacitinib is important to Bristol Myers for several reasons. The drug is seen as a potential top-seller, leading a new class of oral drugs that …

Continue Reading →